Oncology Medical News about Advanced gastric cancer, docetaxel, cisplatin, fluorouracil

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma
Medical Oncology, 08/03/09

Özdemir NY et al. - In a trial to assess the use of modified standard doses of docetaxel, cisplatin, 5-fluorouracil (mDCF) to evaluate the effectiveness and side effects in advanced gastric adenocarcinoma, it was reported that mDCF might have comparable efficacy with classical DFC, with better toxicity profile. However, its small size and retrospective nature should be considered when interpreting the results.

Methods

37 advanced gastric cancer pts treated with at least 1 course of mDCF protocol as first-line treatment were included.
mDCF protocol included 60 mg/m2 docetaxel and cisplatin for 1 day and 600 mg/m2/day, 5-flourouracil infusion for 5 days, repeated every 3 wks.
No pts used prophylactic granulocte-colony stimulating factor.

Results

Of the pts, 28 were male and 9 were female; median age was 53 yrs.
83.8% received at least 4 courses of chemotherapy and 64.9% completed preplanned 6 courses of treatment.
11 (29.7%) of those pts who received mDCF in the first-line treatment used the FOLFIRI (5-FU, folinic acit, irinotekan) regimen for second-line treatment.
Response rates were evaluated according to RECIST criteria in 30 of 37 pts.
Median follow-up time was 7.1 mos; longest follow-up time was 19.9 mos.
2 pts (5.4%) had complete response, 9 (21.6%) had partial response, and 14 (37.9%) had stabilized disease; the disease was controlled in 25 pts (64.9%) whereas 5 pts (13.5%) had progression.
Median time to progression was 6.7 mos and overall survival was 10 mos.
Assessment of pts for grade 3–4 toxicity revealed that while 5.4% had anemia and 8.1% had neutropenia, 5.4% nausea and 5.4% diarrhea.
Neutropenic fever developed in 2 pts, requiring hospitalization; G-CSF was used in 3 pts.
2 pts with neutropenic fever and 2 with severe anemia received delayed chemotherapy.
Dose reduction was required in 4 pts (10.8%), 1 due to neutropenia, 1 due to nephrotoxicity, and 2 due to nausea.